文献速递贫血与红细胞疾病MDS 与骨髓增殖性肿瘤

两例无明确髓系肿瘤的VEXAS综合征临床、组织病理与分子研究

A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm.
PubMed 文献 · Blood Adv · 2022-01-01

本文报告两例无明确髓系肿瘤的VEXAS综合征患者的临床、组织病理和分子特征。患者表现为大细胞性贫血、血小板减少、骨髓增生活跃伴粒细胞增生、红系前体巨幼样变及髓系和红系前体细胞显著空泡化,且未见hematogones。识别这些血液学特征有助于提高对该罕见病的诊断意识并改善临床结局。

要点

  • VEXAS综合征可无明确髓系肿瘤,骨髓特征包括髓系和红系前体细胞空泡化。
  • 典型血液学表现包括大细胞性贫血、血小板减少和骨髓粒细胞增生。
  • 红系前体巨幼样变和hematogones缺失可为诊断提供线索。

核心结论

  • VEXAS综合征患者即使无明确髓系肿瘤,也具有特征性血液学表现,有助于提高诊断意识。

研究设计与样本

  • 病例报告,描述两例无明确髓系肿瘤的VEXAS综合征患者的临床、组织病理和分子特征。

主要发现

  • 两例患者表现为大细胞性贫血、血小板减少、骨髓增生活跃伴粒细胞增生、红系前体巨幼样变及髓系和红系前体细胞显著空泡化。
  • 骨髓中未见hematogones。

临床怎么用

  • 对成人起病炎症综合征伴血细胞减少和骨髓髓系发育异常者,应警惕VEXAS综合征并行UBA1基因检测。
  • 早期诊断有助于避免难治性炎症综合征相关并发症并改善总体临床结局。

局限性

  • 仅基于两例病例报告,结论的普遍性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

VEXAS (vacuoles, E1 enzyme, X-linked, autoinflammatory, somatic) syndrome is caused by somatic mutations in UBA1 and is identified by a genotype-driven method. This condition affects unrelated men with adultonset inflammatory syndromes in association with hematologic manifestations of peripheral cytopenia and bone marrow myeloid dysplasia. Although bone marrow vacuolization restricted to myeloid and erythroid precursors has been identified in patients with VEXAS, the detailed clinical and histopathological features of peripheral blood and bone marrows remain unclear. The current case report describes the characteristic hematologic findings in patients with VEXAS, including macrocytic anemia, thrombocytopenia, marked hypercellular bone marrow with granulocytic hyperplasia, megaloblastic changes in erythroid precursors, and the absence of hematogones in addition to prominent vacuoles in myeloid and erythroid precursor cells. Characterizing the clinical and hematologic features helps to raise awareness and improve diagnosis of this novel, rare, but potentially underrecognized disease. Prompt diagnosis expands the general knowledgeable and understanding of this disease, and optimal management may prevent patients from developing complications related to this refractory inflammatory syndrome and improve the overall clinical outcome.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Li P, Venkatachalam S, Ospina Cordona D, et al. A clinical, histopathological, and molecular study of two cases of VEXAS syndrome without a definitive myeloid neoplasm. Blood Adv. 2022. PMID: 34649277. doi:10.1182/bloodadvances.2021005243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。